烟酸缓释剂与阿托伐他汀联合治疗急性冠脉综合征合并高脂血症患者100例疗效分析(2)
 |
| 第1页 |
参见附件(1053KB，2页)。
尽管升高HDL是一种很有前途的策略，但还有多个问题需要澄清。比如HDL不同类型是否有不同意义；HDL是如何发挥其保护作用等，这些问题我们还没有完全明了，我们知道HDL能起保护作用，但确切机制并不清楚，这方面迄今仍缺乏大规模的临床试验研究，目前关于HDL作用中涉及基因的研究可能会发现新的治疗靶点。近年来国外已经有他汀/烟酸复合制剂投入市场，包括Advicor、Nicostatin等，烟酸缓释剂与他汀类的联合治疗也期待着更大规模的临床试验研究、长期的随访和持续的安全性监测。
[参考文献]
[1]Vittone F, Chait A, Morse JS, et al. Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS)[J]. J Clin Lipidol,2007,1(3):203-210.
[2]Langslet G, Reikvam A. Can cardiovascular events be prevented by
raising HDL cholesterol[J]. Tidsskr Nor Laegeforen,2008,128(13):1519-1523.
[3]Aronow WS. Treatment of high-risk older persons with lipid-lowering drug therapy[J]. Am J Ther,2008,15(2):102-107.
[4]Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels[J].Heart,2008,94(6):706-714.
[5]Chrysant SG, Ibrahim M. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol[J]. J Clin Hypertens (Greenwich),2006,8(7):493-501.
[6]Sharma M, Sharma DR, Singh V, et al. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study[J]. Vasc Health Risk Manag,2006,2(1):87-93.
[7]Zhao XQ, Morse JS, Dowdy AA , et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)[J]. Am J Cardiol,2004,93(3):307-312.
(收稿日期：2008-08-18)
您现在查看是摘要介绍页，详见PDF附件(1053KB，2页)。